220 related articles for article (PubMed ID: 24562575)
1. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
[TBL] [Abstract][Full Text] [Related]
2. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
3. Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice.
Naiki T; Asamoto M; Toyoda-Hokaiwado N; Naiki-Ito A; Tozawa K; Kohri K; Takahashi S; Shirai T
Prostate; 2012 Apr; 72(5):533-41. PubMed ID: 21748757
[TBL] [Abstract][Full Text] [Related]
4. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
[TBL] [Abstract][Full Text] [Related]
7. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.
Kang M; Lee HS; Lee YJ; Choi WS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Urology; 2015 Jan; 85(1):273.e9-15. PubMed ID: 25440760
[TBL] [Abstract][Full Text] [Related]
8. Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasis.
Suzuki S; Pitchakarn P; Ogawa K; Naiki-Ito A; Chewonarin T; Punfa W; Asamoto M; Shirai T; Takahashi S
Toxicology; 2013 Sep; 311(3):115-23. PubMed ID: 23867582
[TBL] [Abstract][Full Text] [Related]
9. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
10. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Saad F; Fizazi K
Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
[TBL] [Abstract][Full Text] [Related]
11. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
12. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
13. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
14. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
Jeong JH; Park SJ; Dickinson SI; Luo JL
Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
[TBL] [Abstract][Full Text] [Related]
15. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
16. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
[TBL] [Abstract][Full Text] [Related]
17. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
18. Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
Braadland PR; Grytli HH; Ramberg H; Katz B; Kellman R; Gauthier-Landry L; Fazli L; Krobert KA; Wang W; Levy FO; Bjartell A; Berge V; Rennie PS; Mellgren G; Mælandsmo GM; Svindland A; Barbier O; Taskén KA
Oncotarget; 2016 Jan; 7(2):1878-94. PubMed ID: 26646591
[TBL] [Abstract][Full Text] [Related]
19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
20. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]